PD-1 blockade combined with bortezomib compared to single PD-1 blockade in the treatment of relapsed or refractory classical Hodgkin's lymphoma: a prospective cohort study

PD-1 blockade combined with bortezomib in the treatment of relapsed or refractory classical Hodgkin's lymphoma

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900025232

Enrollment

Unknown

Registered

2019-08-17

Start date

2019-08-26

Completion date

Unknown

Last updated

2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

relapsed or refractoryHodgkin's lymphoma

Interventions

First cohort:PD-1 blockade

Second cohort:PD-1 blockade combined with bortezomib

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histologically confirmed diagnosis of classical Hodgkin's lymphoma that is relapsed or refractory; 2. ECOG performance status of 0 or 1; 3. Failed at least2 prior therapies including cytotoxic chemotherapy, autologous hematopoietic stem cell transplantation, brentuximab vedotin, allogeneic hematopoietic stem cell transplantation without active graft versus host disease; 4. Patients have received the tharapy of PD-1 blockade combined with bortezomib or single PD-1 blockade for the treatment of relapsed or refractory classical Hodgkin's lymphoma, and patients are willing to participate in the follow-up of this cohort study.

Exclusion criteria

Exclusion criteria: Patients are not willing to participate in the follow-up of this cohort study

Design outcomes

Primary

Measure	Time frame
complete remission;Partial response;	—

Countries

China

Contacts

Public ContactYongqian Jia

West China Hospital, Sichuan University

jia_yq@scu.edu.cn+86 18980601198

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026